€3.45
Your prediction
Esperion Therapeutis.Inc. Stock
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Pros and Cons of Esperion Therapeutis.Inc. in the next few years
Pros
Cons
Performance of Esperion Therapeutis.Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 2.220% | 32.003% | 35.720% | 40.058% | 54.205% | -48.536% | -85.077% |
| Ardelyx Inc. | 0.940% | 6.963% | 17.623% | -4.385% | 3.646% | 189.622% | 2.592% |
| Krystal Biotech | 0.480% | 6.716% | 15.870% | 1.639% | 24.244% | 148.816% | - |
| Evolus Inc | 0.000% | 1.695% | -1.639% | -49.153% | -42.857% | -16.667% | 90.235% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financial outlook for Esperion, a biotechnology firm operating in the medical research arena, presents a mix of challenges and opportunities. The company exhibits a precarious position characterized by negative equity and substantial net losses, raising essential questions about its long-term viability. However, despite these challenges, there are factors worthy of consideration that could shape its future trajectory.
Pros
Market Capitalization and Revenue Growth: Esperion boasts a market capitalization of approximately $406 million, which can indicate a degree of confidence from investors, particularly in the biotechnology sector known for its volatility. Additionally, the company reports a quarterly revenue growth rate of 4.66% year-over-year, suggesting that it may be building momentum despite current operational losses.
Comments
News
Esperion (ESPR) Q2 Revenue Jumps 12%
Esperion Therapeutics (NASDAQ:ESPR), a specialty pharmaceutical company focused on cardiovascular disease, delivered higher-than-expected GAAP results in its latest earnings release. On August 5
